KRAS抑制剂的全球市场:药价,销售额,临床试验趋势(2029年)
市场调查报告书
商品编码
1210856

KRAS抑制剂的全球市场:药价,销售额,临床试验趋势(2029年)

Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029

出版日期: | 出版商: KuicK Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

本报告提供全球KRAS抑制剂市场相关调查,市场概要,以及药物趋势,临床试验趋势,各地区趋势,及加入此市场的主要企业的竞争情形等资讯。

目录

第1章 KRAS抑制剂的简介

  • KRAS抑制剂的开发
  • 作用机制

第2章 癌症治疗的KRAS抑制剂所扮演的角色

  • 肺癌
  • 胰臟癌
  • 大肠癌
  • 其他的癌症

第3章 Lumakras-最初已批准KRAS抑制剂

  • 概要与专利的洞察
  • 剂量与价格分析
  • 销售额分析

第4章 第Krazati-2号已批准KRAS抑制剂

  • 概要与专利的洞察
  • 剂量与价格分析

第5章 全球KRAS抑制剂市场预测

  • 目前市场情境
  • 未来市场机会

第6章 KRAS抑制剂市场各地区分析

  • 美国
  • 英国
  • 中国
  • 欧洲
  • 日本
  • 韩国
  • 加拿大

第7章 世界的KRAS抑制剂的临床实验平台概要

  • 各国
  • 各相
  • 各企业
  • 各适应症
  • 各患者市场区隔

第8章 全球KRAS抑制剂的临床实验平台,各企业,各适应症,各相

  • 研究
  • 前临床
  • 第一阶段
  • 第一/二阶段
  • 第二阶段
  • 第三阶段

第9章 已上市的KRAS抑制剂的临床性洞察

  • Sotorasib - Amgen
  • Adagrasib - Mirati Therapeutics

第10章 全球KRAS抑制剂市场动态

  • KRAS抑制剂的市场促进因素和机会
  • KRAS抑制剂市场课题

第11章 竞争情形

  • Array BioPharma
  • Applied Pharmaceutical Science
  • Amgen
  • AnBogen Therapeutics
  • Ascentage Pharma
  • AstraZeneca
  • BridgeBio Pharma
  • Boehringer Ingelheim
  • Erasca
  • Carmot Therapeutics
  • FogPharma
  • Frontier Medicines
  • Jacobio Pharmaceuticals
  • Jemincare
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Medicine Co.
  • Leidos Biomedical Research
  • Mirati Therapeutics
  • REVOLUTION Medicines
  • Roche
  • Shanghai Euregen Biopharma
  • Shanghai Yingli Pharmaceutical
  • Singh Biotechnology
  • Suzhou Genhouse Bio
  • Suzhou Zelgen Biopharmaceuticals

“Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029” Report Highlights:

  • Global KRAS Inhibitors Market Opportunity > USD 4 Billion By 2029
  • Global KRAS Drug Market Growth In 2022 > 200%
  • Number Of Approved Drugs: 2 Drugs
  • Approved Drug Global & Regional Sales Insight
  • Approved Drugs Patent, Price & Dosage Analysis
  • Regional Analysis: USA, UK, China Europe, Japan, South Korea
  • Number Of Drugs In Clinical Trials: > 60 Drugs
  • Insight On All Drugs In Clinical Trials By Phase, Company, Country, Indication & Patient Segment

The advancement in the field of biology has led to the discovery of several oncogenes that play a critical role in cancer development and thus presenting researchers with opportunities to target them. KRAS is one such oncogene that is the most frequently mutated and therefore, specific research and clinical activities are being carried out for possibly development of novel KRAS inhibitors. The future pipeline of this target looks flourishing as several pharmaceutical companies also plan on bringing novel drug candidates against KRAS.

Researchers over the world have known about KRAS mutations for several years; however, the available therapies against it were proven to be indefinable. But after the approval of first ever KRAS inhibitor, Lumakras (Sotorasib) developed by Amgen in 2021 for treatment of patients with advanced KRAS G12C mutated non-small cell lung cancer, the product market showed significant growth in terms of both commercial sale success and enhanced overall survival rates. Its sales grew more than twice in 2022 as compare to 2021 levels. The drug is the first ever targeted anti-cancer treatment drug against KRAS mutations.

Furthermore, Qiagen also launched Therascreen KRAS RGQ PCR Kit after it received US regulatory approval as a companion diagnostic in aiding the diagnosis of non-small cell lung cancer. This was the first companion diagnostic kit to have received premarket approval from the US FDA. Nevertheless, additional progress has been made in the industry and FDA has further approved companion diagnosis kits. In December, 2022 Agilent Resolution's ctDx FIRST was granted approval by the FDA as a companion diagnostic for patients with NSCLC.

The ever increasing cases of cancer and the ability of the tumor to develop new and frequent mutations signifies an unmet need for advancement of novel therapies in the management and treatment of cancer. However, with discoveries like that of Kristen rat sarcoma viral oncogene homolog (KRAS), the future of cancer targeted therapies is something to look forwards. It is both interesting and concerning how KRAS mutations play a significant role in the pathogenesis and proliferation of cancer.

With booming research and development strategies, pharmaceutical companies are rapidly moving forward and aiming this oncogene. Recently, VITRAC Therapeutic has initiated a phase I clinical trial with AURKA Inhibitor VIC-1911 and Sotorasib a G12C inhibitor for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). This study of VIC-1911 as monotherapy and in combination with Sotorasib is being performed at Yale Cancer Centre. The preclinical studies have strongly supported the combinational use of both the drugs and by using this multi-targeted approach, the study aims to provide a more effective therapeutic outcome for patients with KRAS G12C-mutated NSCLC.

The market for KRAS targeted drugs is poised with exponential growth with several factors determining its potential. The KRAS market is widely supported by accelerating trend of preclinical and in vitro studies which has increased the number of patients that are seeking out treatment opportunities. The rising demand for this therapy has resulted in increasing acceptance of cancer managing treatments. The market expects new medications to swiftly and rapidly enter the commercial sector.

There are also factors that will be challenging the future potential of this market. With increased research and development activity, there also increases the number of competitors in the market. Drug manufacturers need to develop medications that have innovation and creativeness and the ability to show better outcomes than its opponents. Currently, Amgen is in the lead for KRAS targeted therapy market but with the incoming of more drugs in the future, some challenges are bound to be faced by the company if it wants to keep its position as the topmost stakeholder in the KRAS inhibitors drug market.

For instance, on December 2022, the US FDA granted accelerated approval to Mirati Therapeutics' Adagrasib (Krazati) which is a RAS GTPase family inhibitor for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval was based on KRYSTAL-1, a multicenter, open label clinical trial and the indication was approved under accelerated approval based on the overall response rate and duration of response.

This report aims to provide an in depth analysis about the current market scenario of KRAS targeted therapies and the future potential this segment holds. Overall, as per our analysis, the market for KRAS inhibitors will see an exponential growth mainly attributed by the robust research and development activities in this domain as well as the presence of strong clinical pipeline of drugs candidates. The report sheds light on the factors that will propel the markets growth as well as factors that will be challenging the market opportunity.

Table of Contents

1. Introduction to KRAS Inhibitors

  • 1.1. Development of KRAS Inhibitors
  • 1.2. Mechanism Of Action

2. Role of KRAS Inhibitors in Cancer Therapy

  • 2.1. Lung Cancer
  • 2.2. Pancreatic Cancer
  • 2.3. Colorectal Cancer
  • 2.4. Other Cancers

3. Lumakras - First Approved KRAS Inhibitor

  • 3.1. Overview & Patent Insight
  • 3.2. Dosage & Price Analysis
  • 3.3. Sales Analysis

4. Krazati - Second Approved KRAS Inhibitor

  • 4.1. Overview & Patent Insight
  • 4.2. Dosage & Price Analysis

5. Global KRAS Inhibitor Market Outlook

  • 5.1. Current Market Scenario
  • 5.2. Future Market Opportunity

6. KRAS Inhibitor Market Regional Analysis

  • 6.1. US
  • 6.2. UK
  • 6.3. China
  • 6.4. Europe
  • 6.5. Japan
  • 6.6. South Korea
  • 6.7. Canada

7. Global KRAS Inhibitors Clinical Pipeline Overview

  • 7.1. By Country
  • 7.2. By Phase
  • 7.3. By Company
  • 7.4. By Indication
  • 7.5. By Patient Segment

8. Global KRAS Inhibitors Clinical Pipeline By Company, Indication & Phase

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Phase-I
  • 8.4. Phase-I/II
  • 8.5. Phase-II
  • 8.6. Phase-III

9. Marketed KRAS Inhibitors Clinical Insight

  • 9.1. Sotorasib - Amgen
  • 9.2. Adagrasib - Mirati Therapeutics

10. Global KRAS Inhibitors Market Dynamics

  • 10.1. Market Drivers & Opportunities for KRAS Inhibitors
  • 10.2. Challenges for KRAS Inhibitors Market

11. Competitive Landscape

  • 11.1. Array BioPharma
  • 11.2. Applied Pharmaceutical Science
  • 11.3. Amgen
  • 11.4. AnBogen Therapeutics
  • 11.5. Ascentage Pharma
  • 11.6. AstraZeneca
  • 11.7. BridgeBio Pharma
  • 11.8. Boehringer Ingelheim
  • 11.9. Erasca
  • 11.10. Carmot Therapeutics
  • 11.11. FogPharma
  • 11.12. Frontier Medicines
  • 11.13. Jacobio Pharmaceuticals
  • 11.14. Jemincare
  • 11.15. Jiangsu Hansoh Pharmaceutical
  • 11.16. Jiangsu Hengrui Medicine Co.
  • 11.17. Leidos Biomedical Research
  • 11.18. Mirati Therapeutics
  • 11.19. REVOLUTION Medicines
  • 11.20. Roche
  • 11.21. Shanghai Euregen Biopharma
  • 11.22. Shanghai Yingli Pharmaceutical
  • 11.23. Singh Biotechnology
  • 11.24. Suzhou Genhouse Bio
  • 11.25. Suzhou Zelgen Biopharmaceuticals

List of Figures

  • Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
  • Figure 1-2: Historical Development of KRAS Inhibitors
  • Figure 1-3: General Mechanism of KRAS Inhibitors against Cancer
  • Figure 1-4: Targeting Approaches of KRAS Inhibitors
  • Figure 1-5: Direct Targeting of Mutant KRAS
  • Figure 1-6: Targets for Modifying the KRAS Membrane Association
  • Figure 2-1: KRAS Mutational Frequency by Organs (%)
  • Figure 2-2: Roles of KRAS Inhibitors in Cancer Treatment
  • Figure 2-3: Global - Estimated Newly Diagnosed Lung Cancer Cases & Deaths (Millions), 2020
  • Figure 2-4: Global - Lung Cancer Incidence by Type (%), 2020
  • Figure 2-5: Impact of KRAS Inhibitor on Lung Cancer
  • Figure 2-6: Investigational KRAS Inhibitors for Lung Cancer
  • Figure 2-7: RMC-6291 Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 2-8: Revolution Medicines - KRAS inhibitors & Status
  • Figure 2-9: JAB-21822 Phase I/II Monotherapy Trial - Study Initiation & Expected Completion Year
  • Figure 2-10: JAB-21822 Phase I/II Monotherapy & Combination Therapy Trial - Study Initiation & Expected Completion Year
  • Figure 2-11: JAB-21822 Phase I/II Combination Therapy Trial - Study Initiation & Expected Completion Year
  • Figure 2-12: JAB-21822 Phase I/II Co Mutation Trial - Study Initiation & Expected Completion Year
  • Figure 2-13: Global - Estimated Newly Diagnosed Pancreatic Cancer Cases & Deaths, 2020
  • Figure 2-14: Ideal Targets of Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 2-15: Role of KRAS Inhibitors in Pancreatic Cancer
  • Figure 2-16: Investigational KRAS Inhibitors for Pancreatic Cancer
  • Figure 2-17: siG12D LODER Phase II Trial - Study Initiation & Expected Completion Year
  • Figure 2-18: iExosomes Phase I Trial - Study Initiation & Expected Completion Year
  • Figure 2-19: HBI-2438 Phase I Trials - Study Initiation & Expected Completion Year
  • Figure 2-20: KRAS mTCR PBL Phase I/II Trials - Study Initiation & Expected Completion Year
  • Figure 2-21: Global - Estimated Newly Diagnosed Colorectal Cancer Cases & Deaths (Millions), 2020
  • Figure 2-22: Global - New Colorectal Cancer Incidences By Type (%), 2020
  • Figure 2-23: Ideal Targets for Inhibiting KRAS Mutation of Pancreatic Cancer
  • Figure 2-24: Investigational KRAS Inhibitors for Colorectal Cancer
  • Figure 2-25: KRAS mTCR PBL Phase I/II Trials - Study Initiation & Expected Completion Year
  • Figure 2-26: IBI351 Phase Ib Trial - Study Initiation & Expected Completion Year
  • Figure 2-27: Global - Estimated Newly Diagnosed Leukemia & Lymphoma Cases & Deaths (Millions), 2020
  • Figure 2-28: US - Estimated New Hodgkin and Non Hodgkin Lymphoma Cases & Deaths (Millions), 2022
  • Figure 2-29: Frequency of KRAS Mutation in Hematological Cancer (%)
  • Figure 2-30: Global - Newly Diagnosed Prostate Cancer Cases & Deaths (Millions), 2020
  • Figure 2-31: Global - Number of Newly Diagnosed Gastric Cancer Cases & Deaths (Millions), 2020
  • Figure 2-32: Global - Number of Newly Diagnosed Endometrial Cancer Cases & Deaths (Millions), 2020
  • Figure 2-33: Global - Gynecological Cancer Incidence By Type, 2020
  • Figure 2-34: Global - Newly Diagnosed Cases & Deaths related to Brain Cancer (Millions), 2020
  • Figure 3-1: Lumakras - Approval Year By Region
  • Figure 3-2: US - Lumakras Patent Filing & Expiration Year
  • Figure 3-3: US - Lumakras FDA Approval & Patent Exclusivity Year
  • Figure 3-4: US - Number Of Physicians Prescribing Lumakras Annually, 2021 & 2022
  • Figure 3-5: US - Number Of Patients Getting Prescribed Lumakras Annually, 2021 & 2022
  • Figure 3-6: US - Number Of Physicians Prescribing Lumakras Annually Quarterly, 2022
  • Figure 3-7: US - Number Of Patients Getting Prescribed Lumakras Quarterly, 2022
  • Figure 3-8: US - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (US$), February'2023
  • Figure 3-9: UK - Price for 240 Tablet Lumakras Supply & Price Per Unit of 120mg Tablet (GBP/US$), February'2023
  • Figure 3-10: US - Monthly & Annual Treatment Cost with Lumakras (US$), February'2023
  • Figure 3-11: Lumakras - Recommended Initial & Reduced Dose (mg/day)
  • Figure 3-12: Global - Lumakras/Lumykras Annual Sales (US$ Million), 2021-2022
  • Figure 3-13: Global - Lumakras/Lumykras Sales by Region (US$ Million), 2022
  • Figure 3-14: Global - Lumakras/Lumykras Annual Sales by Region (%), 2022
  • Figure 3-15: Global - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
  • Figure 3-16: US - Lumakras/Lumykras Annual Sales (US$ Million), 2021 - 2022
  • Figure 3-17: US - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
  • Figure 3-18: ROW - Lumakras/Lumykras Quarterly Sales (US$ Million), 2022
  • Figure 4-1: US - Adagrasib Patent Filing & Publication Year
  • Figure 4-2: US - WAC Price for 180-Tablet Krazati Supply & Price Per Unit of 200mg Tablet (US$), January'2023
  • Figure 4-3: Krazati - Recommended Initial & Reduced Dose (mg/day)
  • Figure 4-4: US - Estimated Monthly & Annual Treatment Cost with Krazati (US$), January'2023
  • Figure 5-1: Global - Cancer Incidences & Deaths (Million), 2020
  • Figure 5-2: Global - KRAS Inhibitor Market (US$ Million), 2021 & 2022
  • Figure 5-3: Global - KRAS Inhibitor Market Size by Region (US$ Million), 2022
  • Figure 5-4: Global - KRAS Inhibitor Market Size (US$ Million), 2023 - 2029
  • Figure 6-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-2: US vs. ROW - KRAS Inhibitor Market Size (US$ Million), 2022
  • Figure 6-3: US vs. ROW - KRAS Inhibitor Market Size (%), 2022
  • Figure 6-4: US - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-5: UK - Cancer Incidences & Deaths, 2020 & 2025
  • Figure 6-6: UK - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-7: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-8: China - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-9: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-10: Europe - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-11: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-12: Japan - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-13: South Korea - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-14: South Korea - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 6-15: Canada - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-16: Canada - KRAS Inhibitor Market Size (US$ Million), 2022 - 2029
  • Figure 7-1: Global - KRAS Protein inhibitors Clinical Trials by Country, 2023 -2029
  • Figure 7-2: Global - KRAS Protein inhibitors Clinical Trials by Phase, 2023 -2029
  • Figure 7-3: Global - KRAS Protein inhibitors Clinical Trials by Company, 2023 -2029
  • Figure 7-4: Global - KRAS Protein inhibitors Clinical Trials by Indication, 2023 -2029
  • Figure 7-5: Global - KRAS Protein inhibitors Clinical Trials by Patient Segment, 2023 -2029
  • Figure 10-1: Drivers for KRAS Inhibitor Market
  • Figure 10-2: Challenges for KRAS Inhibitor Market
  • Figure 10-3: US - Estimated Monthly Treatment Cost of Lumakras & Krazati v/s Other Cell Signal Targeting Therapeutics